ClinicalTrials.gg
RecruitingNCT07043088Updated Sep 2, 2025

The SWEEP Trial: a Randomized Controlled Trial

An interventional study of Membrane sweeping in Membrane Stripping, Cervical Ripening and Memrane Sweeping, sponsored by University of Aarhus. Recruiting at 2 sites in Denmark. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-09-02.

Sponsored by University of Aarhus · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,536
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The purpose of this clinical trial is to determine whether serial membrane sweeping at term is more effective than no membrane sweeping in promoting spontaneous onset of labor.

The primary research question is whether serial membrane sweeping increases the likelihood of birth before gestational age 41+3 with spontaneous onset of labor.

A total of 1536 participants will be randomized between gestational age 39+5 and 40+2 to either no membrane sweeping or up to three membrane sweepings performed 2-3 days apart.

Researchers will collect data from the electronic medical record and participants will be asked to complete a short daily questionnaire on pregnancy symptoms and, in the intervention group, their experience of membrane sweeping from randomization until birth. All participants will be asked to complete a follow-up questionnaire about their birth experience five weeks postpartum

Read the detailed description

Background and Objective:

Membrane sweeping is a simple mechanical procedure used at term to promote spontaneous onset of labor by stimulating local prostaglandin release. Although it is widely used and generally considered safe, evidence for its effectiveness is limited and of low certainty. The SWEEP trial is a multicenter randomized controlled trial designed to address this gap by investigating whether serial membrane sweeping starting between GA 39+5 and 40+2 increases the likelihood of spontaneous labor before GA 41+3 compared to no membrane sweeping.

Study design:

This is a pragmatic, open-label, multicenter, randomized controlled trial conducted in public antenatal clinics in Denmark. A total of 1536 pregnant women with low-risk, singleton pregnancies will be randomized between GA 39+5 and 40+2 to either: No membrane sweeping, or serial membrane sweeping with 2-3 days interval, max. three times.

Intervention and Procedures:

If possible, the first membrane sweeping will be performed during the routine antenatal visit at term. If not feasible, a separate consultation will be arranged. Two additional appointments will be scheduled as needed. Membrane sweeping is performed by inserting one or two fingers through the cervix and rotating them 2-5 times to separate the fetal membranes from the lower uterine segment. If the cervix is closed, cervical massage is performed externally with circular motions for approximately 15 seconds.

The intervention will continue until spontaneous labor begins or a maximum of three sweepings have been performed.

Participants in the control group will receive routine midwifery care but will be asked to avoid membrane sweeping until at least GA 41+3, unless medically indicated.

Inclusion criteria:

Singleton pregnant women at term with a fetus in cephalic presentation and an intended vaginal delivery.

Exclusion criteria:

\< 18 years of age Unable to speak and understand Danish Gestational age not determined by Crown-Rump-Length Previous cesarean section Ruptured membranes Painful contractions Vaginal bleeding more than bloody discharge Membrane sweeping performed within the last two weeks Already scheduled IOL or any known indication for IOL at or prior to GA 41+3 based on local or national guidelines Known low-lying placenta (placenta located \<3 cm from the internal orifice verified by transvaginal ultrasound)

Outcomes:

The primary outcome is birth \< GA 41+3 with spontaneous onset of labor.

Key secondary outcomes:

Risks and Side Effects:

There are no known serious risks associated with membrane sweeping for either the mother or baby.

Common and mild side effects may include:

Discomfort or mild pain during the procedure (the procedure can be stopped at any time upon request) Light spotting or brown discharge Braxton Hicks contractions

Informed Consent and Ethical Considerations:

Participants will receive both oral and written information in accordance with national and international ethical guidelines. Consent is obtained digitally via the REDCap platform using secure electronic signature technology.

Participants may withdraw consent at any time without consequence. All data are processed in accordance with the Danish Health Act and applicable GDPR regulations.

The study has been approved by the Regional Committees on Health Research Ethics for Central Denmark Region (journal number: 1-10-72-82-24 ) in accordance with Danish law and the Declaration of Helsinki.

Funding:

Funding for the trial is donated by:

Sundhedsdonationer from the Danish health insurance "danmark" with 7,000,000 DKK, The Health Research Foundation of Central Denmark Region with 100,000 DKK The Danish Association of Midwives with 45,931 DKK.

Additional funds will be sought to cover running costs during the trial. The investigators have no financial interests in the funding organizations.

Dissemination:

Study results will be published in international peer-reviewed journals and made publicly accessible in accordance with transparency requirements.

02

Conditions studied

  • Membrane Stripping
  • Cervical Ripening
  • Memrane Sweeping

Browse trials for

Keywords

  • membrane sweeping
  • cervical ripening
  • labor onset
  • term pregnancy
  • induction of labor
  • midwifery
  • randomized controlled trial
  • post-term pregnancy
  • membrane stripping
03

In context

Pregnancy, Prolonged

30 studies on the registry are indexed under Pregnancy, Prolonged; 3 are open to participants now.

This study's planned enrollment of 1,536 is above the median of 128 across 24 interventional studies indexed under Pregnancy, Prolonged.

Browse Pregnancy, Prolonged studies →

Lead sponsor

University of Aarhus is the lead sponsor of 1,303 studies on the registry; 190 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Singleton pregnant women at term with a fetus in cephalic presentation and an intended vaginal delivery.

Exclusion criteria

Exclusion Criteria:

  • \< 18 years of age
  • Unable to speak and understand Danish
  • Uncertain gestational age , defined as gestational age not determined by Crown-Rump-Length
  • Previous cesarean section
  • Ruptured membranes
  • Painful contractions
  • Vaginal bleeding more than bloody discharge
  • Membrane sweeping performed within the last two weeks
  • Already scheduled IOL or any known indication for IOL at or prior to GA 41+3 based on local or national guidelines
  • Known low-lying placenta (placenta located \<3 cm from the internal orifice verified by transvaginal ultrasound)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,536 participants (estimated)

Study arms

  • No intervention
    No membrane sweeping

    Participants allocated to the control group will receive standard antenatal care, which does not include membrane sweeping prior to gestational age 41+3.

  • Experimental
    Membrane sweeping

    Participants allocated to the intervention group will receive standard anetnatal care plus serial membrane sweeping starting from the time of allocation at gestational age 39+5 to 40+2. A total of up to three membrane sweepings will be scheduled, each with an interval of 2-3 calendar days

    Procedure: Membrane sweeping

Interventions

  • ProcedureMembrane sweeping

    Serial membrane sweeping from gestational age 39+5-40+2 with 2-3 days interval and a maximum og three times.

    Also known as: Intervention group

06

What researchers measure

Primary outcomes

  1. Number of Participants with Spontaneous Onset of Labor Resulting in Birth Before 41+3 Weeks of Gestation

    Participants meet the primary outcome if they give birth before gestational age 41 weeks and 3 days, and labor starts spontaneously-defined as either prelabor rupture of membranes (PROM) or contractions leading to cervical dilation, without the use of medical or mechanical induction methods (including artificial rupture of membranes before 4 cm dilation) and without a cesarean section before labor begins

    Time frame: From randomization until time of birth. Assessed at birth

Secondary outcomes

  1. Undelivered at Gestational Age 41+3

    Still pregnant when entering the calendar date of GA 41+3 (deliveries at 41+3 counts as undelivered)

    Time frame: From randomization until time of birth. Assessed at birth.

  2. Gestational Age at Delivery

    Length of gestation at birth in days

    Time frame: From randomization until time of birth. Assessed at birth

  3. Randomization to Delivery Interval

    Hours from randomization to birth

    Time frame: From date of randomization until the date of birth, assessed up to 21 days

  4. Duration of Labor

    Hours from selfreported starting time of contractions or spontaneous rupture of membranes till time of birth

    Time frame: From onset of labor (self-reported contractions or spontaneous rupture of membranes) until time of birth.

  5. Duration of Active Labor

    Minutes from active phase of labor registered in the electronic medical journal to time of birth or minutes from 4-6 cm of cervical dilation and painful contractions to time of birth.

    Time frame: From active phase of labor to time of birth

  6. Induction Of Labor (IOL)

    Labor started with any induction method including AROM \<4 cm

    Time frame: From date of randomization until time of birth. Assessed within 21 days.

  7. Indication for Induction of Labor

    IOL due to: * Late term pregnancy (from GA 41+3-) * Maternal request * Maternal medical indication * Fetal indication * Other indications

    Time frame: From date of randomization until time of birth. Assessed within 21 days.

  8. Spontaneous Rupture of Membranes

    Spontaneous rupture of membranes as primary labor onset occurring before contractions

    Time frame: From date of randomization until time of birth. Assessed within 21 days.

  9. Use of Oxytocin Augmentation

    Use of oxytocin augmentation during labor from more than 4 cm of cervical dilatation

    Time frame: From active phase of labor to time of birth

  10. Intrapartum Temperature equal to or greater than 38.0 degrees Celsius

    Two rectal temperature measurements of 38.0 degrees Celsius or higher, taken at least 30 minutes apart

    Time frame: From labor onset to time of birth

  11. Epidural Analgesia During Labor

    Administration of epidural from onset of labor till time of birth

    Time frame: From labor onset to time of birth

  12. Mode of Delivery

    Spontaneous vaginal delivery; no use of vacuum or forceps. Instrumental vaginal delivery: use of vacuum or forceps. Caesarean section: scheduled or acute

    Time frame: From onset of labor to time of birth

  13. Early Labor Experience

    Self-reported early labor experience measured using the validated Early Labor Experience Questionnaire (ELEQ); total and subscale scores calculated

    Time frame: 4-6 weeks postpartum

  14. Childbirth Experience

    Self-reported childbirth experience measured using the validated Childbirth Experience Questionnaire (CEQ); total and subscale scores calculated.

    Time frame: 4-6 weeks postpartum

Other outcomes

  1. Method(s) used for Labor Induction

    Method(s) used for labor induction: * Prostaglandin * oxytocin \<4 cm of cervical dilatation * cervical ripening catheter * AROM

    Time frame: From date of randomization until time of birth. Assessed within 21 days.

  2. More than One Induction Method used

    Use of \>1 IOL method

    Time frame: From date of randomization until time of birth. Assessed within 21 days.

  3. Intrapartum Administration of Sntibiotics

    Any antibiotics during labor

    Time frame: From labor onset to time of birth

  4. Endometritis Postpartum

    Suspected or confirmed; requires hospital contact and antibiotics

    Time frame: From time of birth to 7 days postpartum

  5. Maternal Mortality

    Death of a female related to pregnancy or its management

    Time frame: Randomization to 42 days postpartum

  6. Maternal Need for Intensive Care

    Admission to an ICU or a unit that provides 24-h medical supervision and is able to provide mechanical ventilation or continuous vasoactive drug support for pregnancy or childbirth related complications

    Time frame: Randomization to 7 days postpartum

  7. Maternal Length of Hospital Stay

    Hours from admission to delivery ward to discharge

    Time frame: From time of birth to discharge from the hospital. Assessed within 42 days.

  8. Postpartum hemorrhage

    Total bleeding in ml. during delivery and up to 2 hours postpartum

    Time frame: From labor onset until 2 hours postpartum.

  9. Uterine Rupture

    Confirmed cases of uterine rupture

    Time frame: Randomization to time of birth

  10. Abruptio Placentae

    Confirmed cases of abruptio placentae

    Time frame: Randomization to time of birth

  11. Decreased Fetal Movements

    Hospital admission due to maternal concern over decreased fetal movements. Includes all cases leading to clinical assessment.

    Time frame: Randomization to time of birth

  12. Telephone Consultations

    Telephone consultations defined as number of inquiries by telephone regarding a clinical pregnancy question from the woman to the delivery unit or antenatal clinic

    Time frame: Randomization to admission for delivery

  13. Outpatient Visits

    Pregnancy-related outpatient visits not part of standard care or intervention

    Time frame: Randomization to admission for delivery

  14. Hospital Admissions

    Pregnancy-related hospital admissions not part of standard care or intervention.

    Time frame: Randomization to admission for delivery

  15. Perinatal Death

    Death within 7 days after birth, with specified type (antepartum, intrapartum, or neonatal), gestational age or age, and cause of death.

    Time frame: Randomization to 7 days postpartum

  16. Serious Neonatal Morbidity

    Composite of serious neonatal morbidity including NICU admission, need for respiratory support, Apgar \<7 at 5 minutes, acidemia, or sepsis.

    Time frame: From time of birth until discharge from the hospital. Assessed within 42 days.

  17. Admission to Neonatal Intensive Care Unit

    Admission to NICU

    Time frame: From time of birth until discharge from the hospital or within the first 72 hours postpartum

  18. Need for Respiratory Support

    Need for respiratory support (intubation and mechanical ventilation, oxygen, continuous positive airway pressure (CPAP), or high-flow nasal cannula (HNFC)) within 72 hours after birth if admitted to a neonatal department.

    Time frame: From time of birth until discharge from the hospital or within the first 72 hours postpartum.

  19. Apgar score < 7 at 5 minutes

    Apgar score \< 7 at 5 minutes

    Time frame: From time of birth until 5 minutes after birth. Assessed 5 minutes after birth.

  20. Neonatal Acidemia

    pH \< 7.10 in a sample of umbilical cord arterial blood or neonatal blood obtained within the first hour after birth.

    Time frame: From time of birth to one hour postpartum

  21. Neonatal Sepsis

    Neonatal sepsis defined as antibiotic treatment continuously for 7 days minimum.

    Time frame: From time of birth until discharge from the hospital or within the first 72 hours postpartum

  22. Membrane Sweeping Received Outside The Trial

    Self-reported membrane sweeping performed outside the study protocol, e.g. by private provider or midwife via custom item in electronic questionnaire

    Time frame: From randomization until time of birth. Assessed 4-6 weeks postpartum

  23. Stated Preference for Future Membrane Sweeping

    Self-reported stated preference for receiving membrane sweeping in a future pregnancy, reported via custom item in electronic questionnaire.

    Time frame: 4-6 weeks postpartum

  24. Term Pregnancy Symptoms

    Daily self-reported presence and severity of predefined term pregnancy symptoms using a custom electronic questionnaire.

    Time frame: From date of randomization until date of birth. Assessed up to 15 days.

  25. Experience of Membrane Sweeping

    Self-reported experience of membrane sweeping using a visual analogue scale (VAS) and supplementary custom items.

    Time frame: From date of randomization until time of birth. Assessed up to three times within 7 days.

  26. Number of membrane sweepings performed

    Total number of membrane sweepings performed * 0 * 1 * 2 * ≥ 3

    Time frame: From randomization until time of birth. Assessed up to 12 days.

  27. Number of cervical massages performed

    Total number of cervical massages performed * 0 * 1 * 2 * ≥ 3

    Time frame: Randomization to time of birth

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data are available from the corresponding author upon reasonable request and in accordance with Danish data protection regulations.

Supporting information: Study protocol, Statistical analysis plan

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Aug 2027, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2025
First posted
Jun 29, 2025
StartActual
Jun 18, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Oct 2027
Last update
Sep 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07043088
Responsible party
Sponsor
First posted
Jun 29, 2025
Start date
Jun 18, 2025
Primary completion
Aug 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Sep 2, 2025

Study contacts

Sofie Gyrup, PhD Student
Contact
sofiegyrup@clin.au.dk
+4522428032
Sidsel Boie, PhD, MD, Consultant
Contact
sidselboie@clin.au.dk
+4560636835
Julie Glavind, PhD, Associate Professor, MD
principal investigator · Aarhus University Hospital, Department of Obstetrics and Gynecology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion